Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 20, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Remission induction in acute myeloid leukemia.

Eytan M Stein1, Martin S Tallman

  • 1Memorial Sloan Kettering Cancer Center, Leukemia Service, New York, NY 10065, USA.

International Journal of Hematology
|July 14, 2012
PubMed
Summary

Achieving complete remission (CR) is crucial for acute myeloid leukemia patients. Novel induction strategies show promise in improving CR rates and patient outcomes beyond the standard 7 + 3 regimen.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Outcomes of Adolescents and Young Adults with AML Treated on Pediatric vs Adult Protocols.

Blood advances·2026
Same author

Detection of MEN1 resistance mutations in cell-free DNA from acute leukemia patients treated with menin inhibitors.

Blood cancer journal·2026
Same author

Lorlatinib-induced remission in refractory acute myeloid leukemia with an anaplastic lymphoma kinase fusion.

Haematologica·2026

Area of Science:

  • Hematology
  • Oncology
  • Clinical Trials

Background:

  • Complete remission (CR) is essential for acute myeloid leukemia (AML) patients before further treatment.
  • The standard induction chemotherapy for AML is the 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 + 3) regimen, established in the 1980s.
  • Attempts to enhance the CR rate and survival outcomes with the 7 + 3 regimen have yielded disappointing results.

Purpose of the Study:

  • To review recent phase III studies evaluating novel induction strategies for AML.
  • To assess the potential of these new strategies in improving CR rates and overall patient survival.
  • To provide an overview of promising advancements in AML induction therapy.

Main Methods:

  • Review of recent phase III clinical trials.
  • Analysis of novel induction chemotherapy regimens for AML.
  • Comparison of outcomes (CR rates, survival) between novel strategies and the standard 7 + 3 regimen.

Main Results:

  • Recent phase III studies are exploring novel induction strategies for AML.
  • These novel approaches demonstrate potential for increasing CR rates.
  • Improvements in disease outcomes are being observed with these new strategies.

Conclusions:

  • Novel induction strategies offer promise for improving AML treatment.
  • These strategies may lead to higher CR rates and better patient outcomes.
  • Further research and implementation of effective induction therapies are critical for AML management.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Related Experiment Videos

Last Updated: May 20, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018